Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North…

By G. Strauss, J. Herndon, M. Maddaus, D. Johnstone, Elizabeth A. Johnson, D. Harpole, H. Gillenwater, D. Watson, D. Sugarbaker, R. Schilsky and 2 more. Journal of Clinical Oncology, 2008

930 citations recorded by the source corpus.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/13045f0e2bf696e747ba5563de47082ae457e76c

Citations in the corpus

• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, neutral): “In stage IB, a small overall benefit was found [68], a subgroup analysis indicated it was mainly due to the outcome in patients with tumours> 4 cm [72, 73].”
• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, neutral): “Data suggest that there is no overall survival (OS) benefit, except for patients with tumours >4 cm in the CALGB 9633 study [25], or patients with tumours >5 cm in the JBR.”